Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene
Living with Alzheimer’s: China’s health time bomb
19 September 2021Vaccine bookings spike after Italy extends Covid pass
19 September 2021Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
